Milan 2012 Programme Registration Exhibition Hotels Exhibitor Listing Satellite Meetings Visa Information
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Comparing limboconjunctival autograft with new limboconjunctival flap techniques in the primer pterygium

Poster Details

First Author: F.Esin TURKEY

Co Author(s):    F. Nuho?lu   B. G   K. Eltutar        

Abstract Details



Purpose:

To compare the recurrence and complication of limboconjunctival autograft with new limboconjunctival flap in the surgical treatment of primer pterygium .

Setting:

?stanbul Education and Research Hospital, Clinic of Ophthalmology, ?stanbul, Turkey

Methods:

132 eyes of 125 patients who had operation as a result of primer pterygium were evaluated retrospectively. The cases were classified into two groups as the group in which limboconjunctival autograft technique is applied (Group 1, n= 79 eyes) and the group in which new limboconjunctival flap technique is applied (Group 2, n=53 eyes). The limboconjunctival flap which was prepared from the upper nasal conjunctiva and which was close to excision field was sutured to the scleral bed by sliding and with 8.0 vicryls in the group 2.

Results:

Fifty- eight (46,6 %) of the patients were female and 67 (53,6 %) of them were male. Pterygium was bilateral in seven cases (5,6 %). The follow-up period of the cases was approximately 8,9 months in the group 1 and 7,1 months in the group 2. The mean age of the cases was 54,6 years range ( 32- 71years). None of the intraoperative cases developed complications. Recurrence was observed in 8 cases (10.1 %) in the group 1 and in 6 cases (11.3%) in the group 2. However it was not statistically significant ( p>0.05).

Conclusions:

There was no difference between limboconjunctival autograft technique and limboconjunctival flap technique in the surgical treatment of primer pterygium. The limboconjunctival flap technique may be more preferable as the period of surgery is shorter and it has fewer complications. FINANCIAL DISCLOSURE?: No

Back to previous

loading Please wait while information is loading.